Are you Dr. Xie?
Join over one million U.S. Physicians, Nurse Practitioners and PAs, already on Doximity.
- Gain access to free telehealth tools, such as our "call shielding" and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
You already have 21 invites waiting! - Read the latest clinical news, personalized to your specialty.
Office
5751 Hoover Blvd
Tampa, FL 33634Phone+1 813-886-8334Fax+1 813-890-0143
Summary
- Dr. Dong Xie, MD is a board certified pathologist in Tampa, Florida. She is currently licensed to practice medicine in Florida, Tennessee, and West Virginia. She is affiliated with Tampa General Hospital and AdventHealth Tampa.
Education & Training
- Ohio State University HospitalFellowship, Dermatopathology, 1998 - 1999
- Ohio State University HospitalFellowship, Blood Banking/Transfusion Medicine, 1997 - 1998
- Ohio State University HospitalResidency, Pathology-Anatomic and Clinical, 1993 - 1997
- Shanghai Medical UniversityClass of 1984
Certifications & Licensure
- FL State Medical License 2000 - 2025
- WV State Medical License 1997 - 2025
- TN State Medical License 2004 - 2018
- American Board of Pathology Anatomic Pathology & Clinical Pathology
- American Board of Pathology Dermatopathology
Publications & Presentations
PubMed
- 126 citationsPreparation and evaluation of a novel glass-ionomer cement with antibacterial functionsDong Xie, Yiming Weng, Xia Guo, Jun Zhao, Richard L. Gregory
Dental Materials. 2011-05-01 - 2 citationsA novel antibacterial zirconia-containing PMMA bone cement.Yong Chen, Gulsah Caneli, Rashed Almousa, Dong Xie
Journal of the Mechanical Behavior of Biomedical Materials. 2022-05-01 - 11 citationsSurface modification of polyurethane with a hydrophilic, antibacterial polymer for improved antifouling and antibacterial function:Dong Xie, Leah Howard, Rashed Almousa
Journal of Biomaterials Applications. 2018-08-08
Press Mentions
- Frontier Biotechnologies' Long-Acting Injectable (Aikening(R)), in a Two Drug Regimen, Proves Safe and Effective for Critically Ill Hospitalized AIDS PatientsOctober 27th, 2021
- Frontier Biotechnologies' First Long-Acting Injectable (Aikening(R)), in a Two Drug Regimen for HIV, Proves Safe and Efficacious for PatientsJuly 19th, 2021